RxDoctor Payments Data

Susan Hoffman, MD

Internal Medicine · Jacksonville, FLNPI 1760459788

Payments from drug & device makers

$422in general payments, 2019–2025

Across 16 payments — averaging $26.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$253
  • Abbott$116
  • Novo Nordisk$20
  • Eisai Inc.$18
  • AstraZeneca$15

What the payments were for

  • Food & beverage$422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insulet Corporation7$253
Abbott6$116
Novo Nordisk1$20
Eisai Inc.1$18
AstraZeneca1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$422 in reported general payments places this provider in the 50th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$158,849
Medicare patients
355
Services billed
3,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$112,836
OzempicSemaglutide84$91,308
RybelsusSemaglutide49$68,064
EliquisApixaban60$59,938
MounjaroTirzepatide39$41,765
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$37,102
Tresiba Flextouch U-200Insulin Degludec26$33,391
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt24$26,560
Tresiba Flextouch U-100Insulin Degludec42$24,345
LinzessLinaclotide16$14,465
TrulicityDulaglutide12$13,434
Synjardy XrEmpagliflozin/Metformin Hcl19$13,370
LyricaPregabalin11$9,349
Novolog FlexpenInsulin Aspart36$8,816
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen269$8,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$20$159,372133 claims
AstraZenecaFarxiga, Symbicort$15$9,90524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →